CD8A and prostate carcinoma: While the success of checkpoint inhibitors has been modest in the treatment of prostate cancer, Graff et al. in a small Phase II trial (n = 10) described two mCRPC patients that showed robust response to anti-PD-1 treatment with baseline tumours having CD8+ T-cell infiltration [65].